Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia

Author
Baune, Bernhard T.
Fanous, Ayman H.
Frank, Josef
Kelly, Brian
McQuillin, Andrew
Melle, Ingrid
Mortensen, Preben B.
Mowry, Bryan J.
Pato, Carlos N.
Periyasamy, Sathish
Rietschel, Marcella
Rujescu, Dan
Simonsen, Carmen
St Clair, David
Tooney, Paul
Wu, Jing Qin
Andreassen, Ole A.
Kowalec, Kaarina
Sullivan, Patrick F.
Murray, Robin M.
Owen, Michael J.
MacCabe, James H.
O'Donovan, Michael C.
Walters, James T. R.
Pardinas, Antonio F.
Smart, Sophie E.
Willcocks, Isabella R.
Holmans, Peter A.
Dennison, Charlotte A.
Lynham, Amy J.
Legge, Sophie E.
Bigdeli, Tim B.
Cairns, Murray J.
Corvin, Aiden
Metadata
Show full item record
Abstract
IMPORTANCE About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resistant schizophrenia (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies of TRS are scarce because of the difficulty in collecting data from well-characterized TRS cohorts.
URI
http://hdl.handle.net/20.500.12627/177647
https://doi.org/10.1001/jamapsychiatry.2021.3799
Collections